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Abstract
Thymidylate synthase (TS) is a well-recognized target for anticancer chemotherapy. Due to its key role in the sole de novo pathway for
thymidylate synthesis and, hence, DNA synthesis, it is an essential enzyme in all life forms. As such, it has been recently recognized as a
valuable new target against infectious diseases. There is also a pressing need for new antimicrobial agents that are able to target strains that
are drug resistant toward currently used drugs. In this context, species specificity is of crucial importance to distinguish between the invading
microorganism and the human host, yet thymidylate synthase is among the most highly conserved enzymes. We combine structure-based
drug design with rapid synthetic techniques and mutagenesis, in an iterative fashion, to develop novel antifolates that are not derived from the
substrate and cofactor, and to understand the molecular basis for the observed species specificity. The role of structural and computational
studies in the discovery of nonanalog antifolate inhibitors of bacterial TS, naphthalein and dansyl derivatives, and in the understanding of
their biological activity profile, are discussed. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Folate-dependent enzymes have always been considered
as attractive targets for hyperproliferative diseases, includ-
ing cancer and infectious diseases [1,2]. Since they are
usually involved in processes related to nucleic acid syn-
thesis, their inhibitors act as antimetabolites, inhibiting cell
division [3]. A problem with the current antimetabolite
drugs is the development of resistance in human and
pathogenic cells. Such resistance has arisen under intense
and continuous chemotherapy, and can diminish or abrogate
the therapeutic responses to these drugs [4]. The mecha-
nisms of drug resistance can be seen both in multidrug
resistant proteins that pump drug molecules out of the cell,
and in mutations in the structural gene for the target itself
that directly diminishes the affinity of the drug for the target
enzyme. In recent years, with the advent of modern tech-
nologies in drug discovery, better understanding of the
molecular basis of drug– target interactions have been
reached and suggest new strategies to solve the above-
mentioned problems [5].
Because of its essential role in DNA synthesis, thymi-
dylate synthase (TS) is among the most studied of folate-
dependent enzymes. We report the development of two
novel classes of inhibitors of TS that were discovered
through structural insights, and that have no roots in the
initial substrate or cofactor. We show how a 100-fold
species selectivity was developed into an antipathogenic
inhibitor by structure-based elaboration.
Thymidylate synthase has a dual function, acting both as
an enzyme and as a regulator of its own expression by binding
and inactivating its own RNA. As a catalytic protein, it
catalyzes the reductive methylation of 2V-deoxyuridine-5V-
monophosphate (dUMP) to 2V-deoxythymidine-5V-mono-
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phosphate (dTMP) [6]. As a regulatory protein, TS may also
be involved in the synthesis of proteins that regulate the
apoptotic process [7,8].
The sequences of the TS enzymes from more than 30
organisms have been determined. Among them, many are
from pathogenic microorganisms that include the fungi
Cryptococcus neoformans and Pneumocistis carinii; para-
sites, Trichinella spiralis, Leishmania major, Tripanosoma
cruzi, Plasmodium malariae; and bacteria, Escherichia coli
and Staphylococcus aureus. Sequence alignment and com-
parisons show that, of 26 residues involved in substrates
binding, 16 are completely conserved, so that TS is one of
the most conserved enzyme known [6]. Therefore, inhibitors
against one species can be used as a starting point for
development of species specific inhibitors, by taking
advantage of the unique features of the active sites of each
pathogenic species.
The inhibition of TS can be accomplished through the
design of molecules that interfere with substrate binding.
After 5-fluorouracil (the active form of which is 5-fluoro-
2V-deoxyuridine-5V-monophosphate, FdUMP) the first
mechanism-based inhibitor of TS introduced in anticancer
chemotherapy, ZD1694 (Fig. 1), a folate-related com-
pound, is effective in clinical therapy against colorectal
cancer. Other molecules with folate-related structures have
been synthesized, including CB3717, GW1843, AG337,
ZD9331, LY21514 (Alimta) [9] (Fig. 1). These molecules
have different metabolism according to how well they can
be transported into the cells through the RFC system, or
other transporter mechanisms. They can be polyglutamy-
lated by folylpolyglutamyl synthetase (FPGS), which
increases their intracellular concentration, and their affin-
ity for the enzyme. Drug resistance mechanisms include
changes in FPGS or in TS itself.
One strategy to sidestep these problems is to design
compounds that avoid the metabolic steps, do not need
activation and bypass the FPGS transporter mechanisms. In
fact, one of the most important mechanisms of resistance is
overproduction of TS due to failure of the feedback regu-
lation of TSmRNA transcription mediated by TS [10].
Fig. 1. Known folate analogs acting as TS inhibitors.
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2. Experimental procedures
Docking calculations were performed with the computer
program DOCK 3.5 using rigid body energy minimization
(500 steps) [11]. Electrostatic and van der Waals interaction
energies were calculated using a potential map calculated by
CHEMGRID. For van der Waals terms, no upper maximum
was set on the interaction energy (i.e., high-energy contacts
were not truncated). For electrostatic terms, a distance-
dependent dielectric constant of 4R was adopted. The
standard AMBER-based parameter set was used [12]. Dock-
ing calculations used crystallographically determined struc-
tures of LcTS in complex with phenolphthalein [13],
compounds a156 and MR20 (Fig. 2). The atoms of these
inhibitors were used as ‘‘sphere centers’’ in these calcula-
tions [14].
Ligand structures were built using SYBYL (Tripos
Associates, St. Louis) without minimization. Partial atomic
charges were calculated using the method of Marsili and
Gasteiger [15].
The hTS model used here was derived from the structure
of E. coli TS [16]. The humanized E. coli TS crystal
structure has been used very successfully as a model of
the human enzyme in previous inhibitor design studies
[17–19].
3. Structure-based design of non analog antifolate
inhibitors
Thymidylate synthase remains a good target for struc-
ture-based drug design [20,21]. Over 90 X-ray crystal
structures have been solved since 1987, when the first X-
ray structure of the apoenzyme from Lactobacillus casei
was determined in Stroud’s laboratory at UCSF in San
Francisco. It was not until 1996 that the first structure of
human TS was determined, initially for the apoenzyme
[22,23]. Unfortunately, it was not suitable for typical anti-
folate drug design because the catalytic loop is twisted
relative to the liganded structure [24,25]. In former years,
to overcome the problem of not having the liganded hTS
structure, scientists used a so-called humanized E.coli TS.
This structure was a modification of the native EcTS in
which some residues involved in ligand binding were
substituted with the corresponding residues from hTS (i.e.,
Glu82 was truncated to alanine, Trp83 was modified to
asparagine and Ile264 was modified to valine, according to
EcTS numbering). Such a structure was suggested to have
the correct sequence/folding for modelling hTS and it was
used to design anticancer compounds [17]. Many leads and
one drug have been discovered so far, using the humanized
EcTS structure, such as the compounds developed at
Agouron. Only recently have the ternary complex of hTS
with dUMP and ZD1694 [24], and the complex with dUMP
and LY21514, been obtained [25]. In principle, it is possible
to rationally design compounds directed to a pathogenic TS
whose X-ray structure is known, e.g., that for P. carinii [26],
taking advantage of the sequence/structure differences with
respect to human TS.
Efforts to discover species-specific inhibitors of TS often
led to folate related compounds with classical nonspecific
biological activity profiles. These molecules, structurally
related to the folate cofactor, inhibit at the same level hTS
and bacterial/fungal TS [27,28].
3.1. Phthalein derivatives discovery
In 1993, Shoichet et al. [13] published a pioneering
structure-based inhibitor search based on application of
docking algorithms to L. casei TS, and searching the
available chemical database using the computational pro-
gram DOCK [14]. For the X-ray ternary complex of LcTS–
dUMP–CB3717, DOCK screened the FCD (Fine Chemical
Directory) database, but notably excluding analogs of the
substrates, i.e., dUMP analogs and folate-related com-
pounds. This led to discovery of phenolphthalein (PTH) as
a low-micromolar inhibitor of LcTS. The biological activity
profile of this molecule was nonspecific: Ki vs. LcTS was
4.7 AM and Ki vs. hTS was 1.3 AM. PTH is a dye and a
well-known laxative agent, so it could not be considered a
lead, but a hit. Nevertheless, it is an interesting molecule
because it suggested that nonfolate related molecules could
bind to the TS binding site with good affinity. The X-ray
crystal structure revealed that this molecule binds compet-
itively, close to the area where CB 3717 binds in the ligand
binding cavity.
Starting from PTH, the design of novel inhibitors of TS
was further developed through a combination of X-ray
structure analysis, database exploration and combinatorial
studies. This led to new candidates that underwent synthetic
optimization and biological evaluation in our hands. In such
a structure-based approach, the knowledge of the 3D struc-
Fig. 2. Naphthalein derivatives acting as nonanalog antifolate inhibitors
(NAAI).
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ture of the target in complex with the evolving compounds
is key to improving the quality and reliability of successive
iterations, as is the feedback from biochemical and bio-
logical screening. Applying these techniques, it was possi-
ble to develop a series of nonfolate analog TS inhibitors that
included naphthalein and dansyl derivatives, as described in
the following sections.
3.2. Naphthalein derivatives
Starting from the X-ray structure of the binary complex
of LcTS with PTH [13], the structure of the ligand was
further modified with other substituents. Small substituents
on the phenolic ring, such as halogens, were introduced and
their biological activity evaluated [29,30]. This led to the
2,3-naphthalein and the 1,8-naphthalein derivatives. With
the latter, the results were most interesting: since introduc-
tion of the substituents on the naphthalene ring and, in
particular, on the phenolic rings, influenced the biological
activity profile, and the ‘affinity fingerprint’ [29]. Applica-
tions of docking algorithms using DOCK suggest that the
naphthalein derivatives bind in the same site as PTH, with
two families of orientations, both close to the classical folate
recognition site. When the compounds were tested, a156
(Fig. 2) inhibited LcTS and EcTS with the same affinity
(Ki = 0.5 AM) while it bound to hTS 40-fold less. This is, to
our knowledge, the first species-specific TS inhibitor. By
contrast, MR20 (Fig. 2) shows the same affinity for bacterial
TS and hTS (Ki = 1 AM) [30]. The structural basis for the
specificity of a156 was investigated by means of X-ray
crystallography, mutagenesis and computation.
The X-ray crystal structure of the binary complex LcTS–
a156 was determined [30]. Surprisingly, this molecule binds
in a different binding site than the parent compound (PTH).
It is shifted 5 A˚ towards the entrance of the active site with
respect to the folate site. In Fig. 3, CB3717 is represented
bound to its crystallographic binding site to show its relative
position with respect to a156.
The X-ray structure of the LcTS–a156 complex differed
from the DOCK prediction, in that the crystallographic
binding mode placed the molecule close to the small
domain, while DOCK placed the same molecule close to
the folate recognition domain. It is well known that DOCK
has such limitations, emphasizing the need for successive
crystal structure determinations as the series progresses.
Nevertheless, this case was not a simple one, since some
experimental results suggested that these molecules could
bind to more than one binding site. Mutagenesis studies
were designed to better understand the mode of action of
these compounds [30]. Residues that represented key inter-
actions with the ligands involved were mutated: V316A,
W82Y and E60D. The three residues are directly or indi-
rectly involved in ligand interactions and direct or long
range effects could be expected. The apparent Ki values
were measured and it was observed that some substitutions
diminished the extent of inhibitor binding from 3- to 20-fold
(V316A and E60D with a156). Several substitutions
improved the extent of inhibitor binding up to 2.5-fold
(E60D with PTH and MR20). These results were ascribed
to multiple binding modes in which these molecules can
bind to more than one binding site with different Ki values.
The crystallographic structure seems most definitive. The X-
ray crystal structure was difficult to obtain and the occu-
pancy (in terms of electron density of the ligand) of the
crystallographic configuration was not complete, suggesting
some disorder or multiple binding configurations [30]. Also,
Fig. 3. Superimposition of the folate analog CB3717 and the nonfolate analogs PTH and a156 in their crystallographic binding configuration in L. casei TS.
The X-ray crystal structures of the three compounds with LcTS have been superimposed to show the different binding configurations.
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the kinetics were difficult to interpret: since some com-
pounds were almost competitive inhibitors with respect to
the folate cofactor, some were ‘mixed’ type inhibitors, while
others were noncompetitive [29].
4. Docking analysis of naphthalein binding
Computational analysis, based on the three X-ray struc-
tures of PTH, a156, MR20 with LcTS, were applied to
define the basis of species specificity. Rigid-body energy
minimization and molecular docking calculations were
performed to investigate how well the compounds fit into
each others’ binding sites, and the analogous sites in a
humanized (see Section 2) E. coli EcTS structure [33]. The
results derived from a comparison with the humanized EcTS
showed how the small domain is especially important in
terms of specificity, since this region is much shorter in the
human enzyme.
4.1. Binding analysis of phthalein derivatives to hTS
When compound a156 is fitted into the human TS
structure, in the same binding site as that of LcTS, it appears
to be poorly accommodated, physically intersecting several
residues. In this orientation in hTS, a156 has a high energy
of interaction due to these steric conflicts. On rigid-body
minimization, which allows the ligand to move as a rigid
body but keeps the receptor rigid, the ligand moved by 4.2
A˚ from its analogous position in hTS, achieving a final
energy that was higher (worse) than when minimized from
its LcTS orientation (Tables 1 and 2). Molecular docking,
which typically allows for further relaxation, could not fit
compound a156 into hTS in a similar orientation as it adopts
in LcTS (data not shown).
Although the complex between LcTS and MR20
involved several residues that differed between the human
and L. casei enzymes, MR20 lacked the steric conflicts with
the humanized E. coli model that compound a156 had
(Table 1). Moreover, compound MR20 had few interactions
with the ‘‘small domain’’ of LcTS. Both observations are
consistent with the low specificity of compound MR20 for
the bacterial vs. the human enzyme. Similar conclusions can
be drawn for PTH, which can be well accommodated in the
humanized EcTS binding site (Table 1).
4.2. Binding of inhibitors to other inhibitors site
In the calculations for LcTS, the question was whether
compounds for which enzyme complex structures were
available could fit well into the binding modes defined by
the other two inhibitors. For instance, how well does PTH fit
into the sites occupied by compounds a156 and MR20, and
how well does compound a156 fit into the site occupied by
compound MR20. The compounds were fitted into the three
different orientations to match equivalent atoms. High-
energy contacts were relaxed through rigid-body minimiza-
tion keeping the conformation of the enzyme constant.
PTH and a156 fitted best in their own crystal structures
of TS, while MR20 fitted equally well in all three sites
(Table 2). Compound a156 showed the highest specificity
for its site, both energetically and in terms of displacement
on rigid body minimization, and compound MR20 showed
the lowest specificity.
4.3. Molecular docking
To investigate the problem more thoroughly, we docked
the individual molecules into crystal structures of LcTS
using the molecular docking program DOCK 3.5 (Table 3)
[11]. DOCK considers multiple orientations of a ligand in a
site and is able to explore possibilities that might be missed
by rigid-body energy minimizations. Docking led to orien-
tations whose geometry corresponded more closely to the
crystallographic result than did the rigid-body minimization
calculations, but did not find geometries that were energeti-
cally more favorable unless we allowed for large deviations
from the canonical binding modes. Considering both energy
and RMS deviation, PTH and compound MR20 showed
little specificity for their own binding sites, whereas com-
pound a156 could only be fitted into its own binding sites; it
could not be fitted into the PTH or compound MR20 sites
unless substantial deviation was allowed.
In conclusion, modeling suggests that the crystallo-
graphic structure of each molecule represents a unique
Table 1
Energies of inhibitors in three different binding modes in the ‘‘humanized’’
E. coli TS structure after rigid body minimization
Ligand Energy in E. coli
site (kcal/mol)a
RMS (A˚)b
PTH  17 2.4
a156  7.6 4.2
MR20  17 2.2
a The structures of the LcTS complexes were RMS-fit on the
‘‘humanized’’ E. coli structure to orient compounds PTH, a156 and
MR20 in the humanized E. coli structure. The positions of the inhibitors
were then allowed to relax as rigid bodies to minimize their interaction
energies with the protein.
b The RMS distance from the initial fit positions to the final energy
miminized positions.
Table 2
Rigid body minimized energies of inhibitors in three different binding
modes













PTH  25.4 0.93  20.9 0.25  18.4 1.98
a156  4.6 1.33  26.7 0.13  14.1 1.68
MR20  18.3 0.9  17.2 1.95  17.4 1.60
a RMS deviation from X-ray crystallographic configuration, or best fit
onto that configuration using common atoms.
M.P. Costi et al. / Biochimica et Biophysica Acta 1587 (2002) 206–214210
low energy binding orientation. Alternatively this family of
molecules might bind to LcTS in several low energy modes,
of which the primary ones are represented by the three
crystal structures. The theory of multiple binding modes is
complex and cannot yet be completely interpreted by energy
calculations, since the inherent errors are large. Therefore
modeling studies have to be considered in light of muta-
genesis and enzymology.
5. Dansyl derivatives discovery
In 1999, a new series of nonfolate analog inhibitors of
LcTS were discovered through a combined approach of
structure-based drug design and in parallel synthetic chem-
istry [31,32]. This approach has the potential to discover new
hits and new scaffolds rapidly for further chemical elabo-
ration toward a specific biological profile [32]. DOCK 3.5
was applied to screen the ACD (Available Chemicals Data-
base) database for compounds that might bind to the binding
site from the ternary complex LcTS–dUMP–CB3717. The
aim was to identify nonfolate chemical structures, and partic-
ularly those suitable for further rapid elaboration by parallel
synthetic chemistry and solid phase methods [33].
Fig. 4. Evolution of the molecular structure of the dansyl derivatives. The fragments in black show the increasing molecular complexity that is related to the
improved affinity for bacterial TS and improved specificity with respect to human TS.
Table 3
Molecular docking energies of inhibitors in three different binding modes













PTH  21.2 0.27  20.6 0.23  20.0 1.55
a156 2.5 1.00  26.7 0.10  18.7 1.39
MR20  20.3 0.79  7.0 1.35  11.5 0.85
a RMS deviation from X-ray crystallographic configuration, or best fit
onto that configuration using common atoms.
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Four hundred molecules with the highest score were
gleaned by this method and scored on the basis of the
electrostatic and van der Waals (VdW) interaction energy
with the enzyme, after correcting for ligand solvation
[12,34]. On the basis of the DOCK score, and the number
of specific interactions with the protein, five hits (IC50
between 300 AM and 2 mM) were tested for their ability
to inhibit LcTS. Among the selected molecules, dansyl
hydrazine (IC50 439 AM; Ki = 176 AM) (Fig. 4) was a good
starting point for synthetic elaboration.
The predicted binding mode for dansyl hydrazine sug-
gested that bulkier fragments attached to the dansyl scaffold
could be accommodated in the enzyme pocket. Among the
more interesting was dansyl tyrosine, with a somewhat
better Ki ( = 65 AM) than dansyl hydrazine (Fig. 4). The
molecule bears both an ‘anchor site,’ a functional group for
linking the scaffold to the resin, and a diversity-derivatizable
group (the carboxyl group and the amino group, respec-
tively). Molecular diversity was introduced in the dansyl
tyrosine molecule by synthesizing a series of analogs that
carry different substituents on the amino group. A library of
34 molecules was created using in-parallel solid phase
synthesis. The best of the synthesized analogs, DDT, had
a Ki of 1.4 AM towards LcTS, while several others had Ki
values below 10 AM. These analogs (Fig. 4) are structurally
dissimilar to either of the substrates but bind competitively
with them.
5.1. Docking of didansyltyrosine to L. casei TS
Further calculations were performed to understand the
molecular basis for DDT affinity: 500 multiple conforma-
tions were generated by rotating all single, nonterminal
bonds in increments of 120j [35]. Each conformer was
independently docked and scored into the LcTS binding
Fig. 5. Superimposition of the X-ray ternary complex EcTS–dUMP–DDT (green yellow) and the DOCK model of DDT (brown blue) with LcTS. The two
molecules are reported in the same frame of reference to show the difference in the respective binding modes: DDT from the X-ray crystal structure is in the
folded conformation and DDT from the DOCK model is oriented towards the entrance to the active site.
Table 4
Inhibitory activity data of dansyl derivatives towards LcTS, EcTS and hTS
Compounds IC50 vs. LcTS IC50 vs. EcTS IC50 vs. hTS
(1) Dansyl hydrazine 458 1114 36
(2) Dansyl tyrosine 163 1170 771
(3) Didansyl tyrosine 3.4 5.0 119
Their specificity profile is represented in the plot, the log IC50 is reported
instead of the IC50, for clarity.
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site. In the best scoring orientation, the anchor dansyl ring
forms nonpolar charge transfer interactions with the pyr-
imidine ring of dUMP.
Increasing the molecular complexity of the dansyl deriv-
atives, the predicted binding mode is conserved, demon-
strating the value of the incremental approach to design new
hits. By adding fragments under computational control, a
sensible gain in binding energy can be observed (from
dansyl hydrazine to DDT, the Ki is improved by 500-fold).
The biological activity profile of the dansyl derivatives
shows the same trend observed in the computational studies
in that increasing the molecular diversity led to rapid
improvement of selectivity (Table 4).
5.2. X-ray crystal structure of EcTS–DDT–dUMP
The crystal structure of the ternary complex DDT–
dUMP–EcTS was subsequently solved at 2.0 A˚ resolution
[36] (Fig. 5). The O-dansyl ring of DDT binds also to the
site normally occupied by the quinazoline group of folate
analogues, as predicted by our model for LcTS, though in a
different orientation. It interacts more deeply in the binding
site due to specific protein rearrangements (i.e., Arg23,
Ala315, dUMP). These deep rearrangements avoid bad
clashes with the inhibitor DDT and could not be predicted
in our present calculations since the receptor was kept rigid.
This underlines the failure of the rigid receptor hypothesis in
drug design.
In the EcTS X-ray structure, the tyrosine ring is oriented
close to Phe228 and Leu224, in the area normally occupied
by the PABA moiety. However, this region is now occupied
by the combination of the phenyl ring and N-dansyl group
of DDT. The phenyl ring and the N-dansyl group form
favourable aromatic stacking interactions with each other
and are sandwiched between the hydrophobic residues
Leu172 and Ile79. Consequently, we encounter several
protein rearrangements in this site, so that the enzyme could
accommodate such a complex moiety (Leu224, Phe228,
Ile81, Leu56, Lys259 are the residues most involved in
protein rearrangements).
The X-ray structure shows that DDT binds to EcTS in a
conformation not predicted by molecular docking studies
and one substantially different from other TS inhibitors.
Binding of DDT is accompanied by large rearrangements of
the protein that involve areas both near and far from the
active site. Not surprisingly, the predicted model for DDT in
LcTS and the crystallographic orientation of DDT in EcTS
differ considerably from each other (Fig. 5). Moreover, the
protein plasticity results in novel interactions of DDT with
residues conserved in bacterial TS but not humanTS and
which are hypothesized to account for DDT’s species
specificity.
The comparison between the binding mode that DDT
displays with the two enzymes, LcTS and EcTS, underlies
the fact that binding of a ligand by a protein is highly
specific, often relying on subtle changes between the
structures of even closely related species of a protein, and
in this case, closely related species of one of the most
conserved of all enzymes, TS.
6. Conclusions
Structure-based drug design is a powerful technique,
especially when combined with mutagenesis and species
specific competition assays. Starting from early hits, it is
possible to discover new scaffolds placing the immediate
computational products alongside the structural analysis of
the crystal/model of the complexes. In the present cases, two
series of compounds were discovered and elaborated to
develop a f 100-fold selective inhibitor for bacterial TSs
vs. human TS. The naphthalein derivatives, after two cycles
of design, synthesis and evaluation, have reached an
advanced stage. The dansyl derivatives are being attractive
probes for structural/functional studies and more efforts are
directed to improve their biological activity profiles.
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